Beacon Investment Advisory Services Inc. slashed its UnitedHealth Group position by 90.4% in the third quarter, offloading 18,239 shares and retaining just 1,938 shares valued at $669,000 as of the reporting date. In contrast, Capitol Advisors Ltd. LLC increased its stake by 4.8% to 1,550 shares ($535,000), HBW Advisory Services LLC added 934 shares for a 7.7% rise to 13,049 shares ($4.506 million), and Cohen Klingenstein LLC purchased 50 additional shares for a modest 0.3% gain to 17,250 shares ($5.956 million). Burns Matteson Capital Management initiated a new position worth $2.768 million, while SWS Partners expanded its holding by 7.2% to 4,325 shares ($1.493 million). Overall, hedge funds and institutional investors control 87.86% of UnitedHealth Group’s outstanding stock. Carnegie Investment Counsel separately boosted its stake by 2.2%, acquiring 2,316 shares and bringing its total to 105,621 shares valued at $36.471 million, underscoring continued confidence among select long-term holders.

In its latest quarter, UnitedHealth Group reported adjusted earnings per share of $2.92, topping consensus forecasts by $0.05, and delivered revenue of $113.16 billion, nearly matching the $113.19 billion analysts had projected. Year-over-year revenue growth of 12.2% contributed to a net margin of 4.04% and a return on equity of 19.23%. On the balance sheet, the company maintains a quick ratio and current ratio of 0.82 each, and a debt-to-equity ratio of 0.71. Market capitalization stands at $300.5 billion, with a price-to-earnings ratio of 17.3, a price/earnings-growth ratio of 2.16 and a beta of 0.43. The 50-day and 200-day simple moving averages sit at $333.71 and $319.10 respectively, while the 52-week trading range extends from $234.60 to $606.36.

UnitedHealth Group declared a quarterly dividend of $2.21 per share, paid to shareholders of record on December 8th and disbursed on December 16th, which annualizes to $8.84 per share and represents a yield of approximately 2.7%. The company’s dividend payout ratio stands at 46.14%, reflecting a balanced approach to returning cash while preserving capital for ongoing investments in its UnitedHealthcare and Optum business platforms. The stable payout underscores management’s commitment to consistent shareholder distributions amid ongoing revenue expansion.

Wall Street sentiment remains cautiously optimistic, with 17 investment analysts assigning Buy ratings, nine on Hold and three on Sell. The consensus price target is $385.54. Notable revisions include Royal Bank of Canada raising its target from $286 to $408 with an Outperform rating, KeyCorp boosting its objective from $350 to $400 and maintaining an Overweight rating, and Mizuho lifting its target from $300 to $430 while reiterating an Outperform stance. Conversely, Deutsche Bank trimmed its rating from Buy to Hold with a $333 target. Goldman Sachs initiated coverage with a Buy recommendation and a $406 price target, reflecting confidence in both near-term earnings resilience and long-term growth drivers within the company’s diversified health services operations.